Condition
Stage III Malignant Mesothelioma|Stage IIIB Non-small Cell Lung Cancer|Stage IV Malignant Mesothelioma|Stage IV Non-small Cell Lung Cancer
Estimated Enrollment: 0
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: OSU-12223|NCI-2014-00637
Study First Received: April 1, 2014
Last Updated: February 1, 2016
Estimated Primary Completion Date: August 2017
Primary Outcome Measures:
Number of patients who received the entire multi-modality regimen|Incidence of grade 4 or greater toxicity in the post-operative period as graded by the National Cancer Institute (NCI) CTCAE (Common Toxicity Criteria for Adverse Effects) version 4.0|Overall survival|Progression-free survival (PFS)|Pleural progression-free survival (PPFS)|Porfimer sodium uptake defined as the ratio of the porfimer sodium concentration in tumor tissue to normal tissue (i.e. skin) using spectrofluorometric assay
Sponsors and Collaborators:
Ohio State University Comprehensive Cancer Center
Website Link: https://ClinicalTrials.gov/show/NCT02106559
